Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study by Patterson, M. C et al.
Patterson et al. Orphanet Journal of Rare Diseases  (2015) 10:65 
DOI 10.1186/s13023-015-0284-zRESEARCH Open AccessStable or improved neurological
manifestations during miglustat therapy in
patients from the international disease
registry for Niemann-Pick disease type C:
an observational cohort study
Marc C Patterson1* , Eugen Mengel2, Marie T Vanier3, Barbara Schwierin4, Audrey Muller4, Peter Cornelisse4,
Mercè Pineda5 and On behalf of the NPC Registry investigatorsAbstract
Background: Niemann-Pick disease type C (NP-C) is a rare neurovisceral disease characterised by progressive
neurological degeneration, where the rate of neurological disease progression varies depending on age at
neurological onset. We report longitudinal data on functional disease progression and safety observations in
patients in the international NPC Registry who received continuous treatment with miglustat.
Methods: The NPC Registry is a prospective observational cohort of NP-C patients. Enrolled patients who received ≥1 year
of continuous miglustat therapy (for ≥90 % of the observation period, with no single treatment interruption >28 days)
were included in this analysis. Disability was measured using a scale rating the four domains, ambulation, manipulation,
language and swallowing from 0 (normal) to 1 (worst). Neurological disease progression was analysed in all patients
based on: 1) annual progression rates between enrolment and last follow up, and; 2) categorical analysis with patients
categorised as ‘improved/stable’ if ≥3/4 domain scores were lower/unchanged, and as ‘progressed’ if <3 scores were
lower/unchanged between enrolment and last follow-up visit.
Results: In total, 283 patients were enrolled from 28 centers in 13 European countries, Canada and Australia between
September 2009 and October 2013; 92 patients received continuous miglustat therapy. The mean (SD) miglustat
exposure during the observation period (enrolment to last follow-up) was 2.0 (0.7) years. Among 84 evaluable patients,
9 (11 %) had early-infantile (<2 years), 27 (32 %) had late-infantile (2 to <6 years), 30 (36 %) had juvenile (6 to <15 years)
and 18 (21 %) had adolescent/adult (≥15 years) onset of neurological manifestations. The mean (95%CI) composite
disability score among all patients was 0.37 (0.32,0.42) at enrolment and 0.44 (0.38,0.50) at last follow-up visit, and the
mean annual progression rate was 0.038 (0.018,0.059). Progression of composite disability scores appeared highest
among patients with neurological onset during infancy or childhood and lowest in those with adolescent/adult-onset.
Overall, 59/86 evaluable patients (69 %) were categorized as improved/stable and the proportion of improved/stable
patients increased with age at neurological onset. Safety findings were consistent with previous data.
Conclusions: Disability status was improved/stable in the majority of patients who received continuous miglustat
therapy for an average period of 2 years.
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Niemann-Pick disease type C (NP-C) is a rare neurovisceral
disease characterized by progressive neurodegeneration
[1, 2]. NP-C is associated with a highly heterogeneous
spectrum of neurological manifestations that can start at
any age [2, 3]. Most published evidence on the disease re-
lates to patients with disease onset during infancy and
childhood, but epidemiological data accumulated over the
last two decades has revealed an increase in the number of
adult-onset cases diagnosed [1, 2]. Disease progression has
been shown to depend on age at onset of neurological man-
ifestations, with early-onset forms progressing faster than
later onset forms [1].
Miglustat (Zavesca®, Actelion Pharmaceuticals Ltd) is a
glucosylceramide synthase inhibitor that was initially ap-
proved for the treatment of Gaucher disease type I [4].
Based on data from a randomized controlled clinical trial
[5], long-term extension studies [6, 7], and a retrospect-
ive observational cohort study [8], miglustat was ap-
proved for the treatment of progressive neurological
manifestations in pediatric and adult patients with NP-C
in the EU in 2009 [4], and has since been approved in a
number of other countries. Observational cohort studies,
case series, and case reports have since supported trial
findings [9–13].
Here we report longitudinal data on functional disease
progression and safety observations from patients who
have been observed in the NPC Registry for ≥1 year and
who were treated continuously with miglustat during
that period.
Methods
The international NPC Registry was initiated in May
2009 as a post-approval commitment to the European
Medicines Agency (EMA) following approval of a new
indication for miglustat for the treatment of progressive
neurological deterioration in adults and children with
NP-C [4]. The Registry is a prospective, observational
cohort study conducted in clinical practice settings. All
patients with a diagnosis of NP-C are eligible for enrol-
ment, regardless of the treatment they receive. A previ-
ous published report from this Registry described
general methodological details and patient characteris-
tics at enrolment [14].
The NPC Registry collects data on demographics,
diagnosis, disease characteristics and treatment. Before
entering any clinical visit data, written informed consent
is obtained from all patients (including children) and/or
their legal guardians.
For the current longitudinal study, data were analyzed for
patients that: 1) received miglustat therapy continuously
between enrolment visit and last follow-up visit (where
‘continuously’ was defined as at least 90 % of the observa-
tion period with no single period without miglustat lastingmore than 28 days); and 2) had a minimum of 1 year of
observation time in the Registry.
Functional disability status is recorded at enrolment
and at each follow-up visit in the Registry using an
expert-based disease-specific disability scale that assesses
four key neurological domains in NP-C (ambulation,
manipulation, language and swallowing) [15]. The scor-
ing system of this scale originally ranged from 0
(normal) to 4 or 5 (worst) [16], but has since been modi-
fied to provide an equal weighting in each domain, and
ranges from 0 (normal) to 1 (worst) [8, 15]. The 0–1
scoring system was chosen for use in the Registry [14] as
this scale has been employed in key studies on the nat-
ural history of NP-C [8, 15], is listed among the useful
assessment tools in the international recommendations
for managing NP-C [2, 3], and has been employed in de-
scribing miglustat treatment outcome on NP-C disease
progression in previous national cohorts [12].
For the current analysis, composite disability scores
were calculated as the mean of all four domains. Disease
progression was assessed by two statistical methods: 1)
annual progression rates were calculated as the change
in composite disability score from enrolment to last
follow-up visit divided by time in years from enrolment
to last follow-up visit; 2) categorical analysis, where pa-
tients were categorized as ‘improved/stable’ when at
least three out of four individual disability domain scores
were decreased or unchanged between enrolment and
last follow-up visit, and patients with fewer than three
out of four domain scores decreased or unchanged were
categorized as ‘progressing’ [8, 15].
Statistical analyses are descriptive. All percentages
were calculated relative to the number of patients with
available data per parameter. Data are presented for all
patients and stratified according to internationally
agreed age at neurological onset categories (early-infant-
ile onset [<2 years], late-infantile onset [2 – <6 years],
juvenile onset [6 – <15 years], and adolescent/adult on-
set [≥15 years]) [1, 2]. One modification to these inter-
nationally agreed neurological onset categories was that
in this analysis all patients with onset aged <2 years were
included in the early-infantile subgroup due to the low
number of cases. The participation rate of miglustat-
treated patients in Europe was calculated as the number
of miglustat-treated patients enrolled in the Registry di-
vided by the estimated number of NP-C patients treated
with miglustat in European countries.Results
Patients
As of the data extraction on 19 October 2013, a total of
283 patients from 28 centers in 13 European countries,
Canada and Australia were enrolled in the NP-C Registry.
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Ninety-two patients received continuous miglustat
therapy between enrolment and last follow-up visit, and
were observed for at least 1 year (Fig. 1). The mean (SD)
observation period was 2.0 (0.7) years. From this point
onwards, all data refer to this continuously treated pa-
tient group (N = 92).
Patient characteristics at enrollment stratified by age at
neurological onset categories are summarized in Table 1.
Amongst all patients, the mean (SD) age at neurological
onset was 9.8 (8.6) years, ranging from <1 year to 44.6 years,
and the mean (SD) age at diagnosis was 13.7 (10.9) years,
ranging from 0.1–44.7 years. Two patients in the late-
infantile subgroup were diagnosed after 20 years of age; ini-
tial neurological symptoms observed between 2 and 6 years
of age were ‘extended daytime sleep periods’ and clumsiness
in one patient, and ’coordination disturbances’ in the other
patient.
Overall the mean (SD) composite disability score at
enrolment was 0.37 (0.23), with scores ranging over the
full scale from 0 (normal function) to 1.0 (maximum
impairment) (Table 1).
Neurological and visceral manifestations prior to or at
enrolment
Almost all patients with available medical history data
had one or more neurological manifestation. The distri-
bution of the most common manifestations was as fol-
lows: ataxia (70 %); vertical gaze palsy (68 %); dysarthria
(63 %); cognitive impairment (56 %); dysphagia (44 %);
dystonia (43 %); seizures (33 %); and cataplexy (24 %).Fig. 1 NPC Registry patient summary. Red box indicates patient cohort anaAs regards visceral symptoms, a history of neonatal
jaundice was reported in 58 % of patients, hepatomegaly
during infancy was reported in 35 %; and splenomegaly
during infancy was reported in 51 %.
Treatment
Amongst the 92 miglustat-treated patients, 82 (89 %) re-
ceived miglustat therapy prior to enrolment, nine (10 %)
initiated miglustat therapy at enrolment, and one patient
started miglustat shortly after enrolment. The mean
(SD) total miglustat exposure between miglustat start
and last follow-up visit was 3.9 (1.9) years (Table 2),
where ‘miglustat start’ was defined as the start of the
most recent, uninterrupted miglustat therapy period
prior to enrolment. Mean (SD) miglustat exposure prior
to enrolment was 1.9 (1.8) years (range 0–7.6 years).
Mean (SD) miglustat exposure during the observation
period (i.e., from enrolment to last follow-up visit) was
2.0 (0.7) years. Mean treatment exposure during the ob-
servation period and mean exposure prior to enrolment
were similar across the neurological-onset subgroups.
Disease progression
Eighty-six patients had available data for the categorical
analysis of disease progression by age at neurological
onset. Ambulation, manipulation, language and swal-
lowing were improved (i.e., decreased score) or stable
(i.e., no change in score) in 75 %, 71 %, 77 % and 74 %
of patients, respectively. Overall, two-thirds (n = 59;
69 %) were categorized as improved/stable (as defined
by at least three out of four disability domains being
decreased or unchanged between enrolment and lastlyzed in this paper
Table 1 Demographics and disease characteristics of all patients receiving continuous miglustat therapy for at least 12 months in
the Registry by neurological onset category
Patients continuously treated with
miglustat (N = 92)
Patients with age at neurological onset data (n = 84)
EI (<2 years) LI (2 – <6 years) JUV (6 – <15 years) AA (≥15 years)
Male: female, n (%) 47 (51.1): 45 (48.9) 5 (55.6): 4 (44.4) 12 (44.4): 15 (55.6) 14 (46.7): 16 (53.3) 10 (55.6): 8 (44.4)
Age at onset of neurological manifestations
n 84* 9 27 30 18
Mean (SD), years 9.8 (8.6) 0.9 (0.7) 4.2 (1.3) 9.8 (2.7) 22.7 (8.8)
Median (range), years 6.9 (<1–44.6) 1.0 (<1 – 2.0) 4.5 (2.0 – 5.9) 9.2 (6.1 – 14.6) 18.7 (15.5 – 44.6)
Age at diagnosis
n 87‡ 9 27 28# 17†
Mean (SD), years 13.7 (10.9) 1.9 (1.9) 7.8 (7.0) 16.6 (7.7) 26.7 (9.9)
Median (range), years 12.0 (0.1–44.7) 1.4 (0.1 – 5.9) 5.2 (0.1 – 28.2)** 13.7 (7.7 – 40.2) 22.1 (14.4 – 44.7)
Age at enrolment
n 92 9 27 30 18
Mean (SD), years 18.9 (11.3) 4.7 (2.3) 12.5 (7.2) 20.7 (8.3) 31.2 (9.2)
Median (range), years 18.8 (0.7–48.3) 4.1 (2.2–8.6) 11.1 (3.6–29.4) 20.7 (9.2–41.5) 29.0 (18.7–48.3)
Composite disability score at enrolment
n 87†† 9 26α 29α 18
Mean (SD) 0.37 (0.23) 0.43 (0.33) 0.32 (0.24) 0.45 (0.22) 0.35 (0.17)
Median (range) 0.35 (0–1.00) 0.52 (0 – 1.00) 0.28 (0 – 1.00) 0.44 (0 – 0.88) 0.29 (0.06 – 0.81)
Composite disability score at last follow up
n 90β 9 27 30 17
Mean (SD) 0.44 (0.27) 0.59 (0.36) 0.46 (0.29) 0.49 (0.24) 0.31 (0.22)
Median (range) 0.36 (0–1.00) 0.58 (0.06–1.00) 0.38 (0.06–1.00) 0.51 (0.00–0.94) 0.29 (0.00–0.88)
*Eight patients had no age at neurological onset data (two with no neurological manifestations at enrolment and six with unknown neurological status); ‡five
patients had no age at diagnosis data, including three for whom age at neurological onset was not available; #two patients had no age at diagnosis data; †one
patient had no age at diagnosis data; **two patients were diagnosed at age >20 years (one had extended daytime sleep periods and clumsiness and the other
had coordination disturbances reported at time of first neurological symptoms). ††five patients had insufficient data, including two for whom age at neurological
onset was not available. αone patient had insufficient data on composite disability score at enrolment; βtwo patients had insufficient disability score data at follow
up. Note: patient age at diagnosis is calculated based on date of the first positive filipin staining or gene mutation analysis result. EI, early-infantile onset; LI, late-
infantile onset; JUV; juvenile onset; AA, adolescent/adult onset
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tients increased across neurological onset categories:
early-infantile (33 %) < late-infantile (50 %) < juvenile
(79 %) < adolescent/adult onset (94 %) (Fig. 2).
The mean (95 % CI) composite disability score among
all patients was 0.37 (0.32, 0.42) at enrolment and 0.44
(0.38, 0.50) at the last follow-up visit. In these patients,
who had received an average of 1.9 years of miglustat
therapy before the observation period, the mean annual
progression rate in composite disability score was 0.038
(0.018, 0.059). The annual progression rate in composite
disability score appeared highest among patients who
had onset of neurological manifestations during infancy
or childhood, and lowest in adolescent/adult-onset pa-
tients (Fig. 3). While Fig. 3 illustrates a visual trend, no
statistical conclusions can be drawn regarding differences
in annual progression rates between the age-at-onset sub-
groups due to the overlap of the 95 % confidence intervals
of the mean rates per subgroup.Safety observations
Safety information recorded during the observation
period is summarized in Table 3; no unexpected safety
findings were identified.
Known safety/tolerability factors associated with miglu-
stat, including chronic diarrhea, thrombocytopenia and
seizures, were frequently reported in the overall population.
Chronic diarrhea (i.e., diarrhea lasting >3 months) occurred
in 11 % of patients during the observation period and in
2 % of patients before treatment. Thrombocytopenia was
recorded in a total of 43 (54 %) patients during follow-up
and in 18 (20 %) patients before miglustat therapy, and was
mild or moderate in almost all (98 %) cases. Seizures were
present in a total of 21 (23 %) patients before miglustat
therapy, and 13 (33 %) patients with available data had new
occurrences of seizures during the observation period.
Tremor was present before miglustat initiation in 23 (25 %)
patients, and two new occurrences of tremor were reported
during follow-up. Neuropathy was present in four (4 %)
Table 2 Miglustat exposure among continuously treated patients by neurological onset category
All patients continuously treated with
miglustat (N = 92)
Patients with age at neurological onset and treatment data
EI (<2 years) LI (2 – <6 years) JUV (6 – <15 years) AA (≥15 years)
Age at 1st miglustat dose, years
n* 82 9 23 27 15
Mean (SD) 16.1 (10.8) 2.9 (1.9) 9.1 (6.9) 19.6 (8.2) 27.1 (8.0)
Range 0.7–44.6 0.8 − 7.4 2.1 − 28.5 9.8 − 41.2 16.3 − 44.6
Pre-enrolment miglustat exposure**, years
n* 91 9 27 29 18
Mean (SD) 1.9 (1.8) 1.7 (1.5) 2.4 (2.1) 1.5 (1.5) 1.7 (1.9)
Range 0–7.6 0.3 − 4.5 0 − 7.6 0 − 4.6 0 − 6.0
Miglustat exposure during follow up†, years
n* 92 9 27 30 18
Mean (SD) 2.0 (0.7) 1.8 (0.4) 1.9 (0.6) 2.3 (0.7) 1.9 (0.5)
Range 1.0–3.7 1.4–2.8 1.1–3.3 1.0–3.7 1.0–3.2
Overall miglustat exposure‡, years
n* 91 9 27 29 18
Mean (SD) 3.9 (1.9) 3.4 (1.42) 4.3 (2.2) 3.9 (1.7) 3.6 (1.9)
Range 1.1–9.8 2.1 − 6.0 1.6 − 9.8 1.3 − 6.8 1.3 − 7.9
*Number of patients with available data (eight patients who had no age at neurological onset data are not included in the age-at-onset subgroup columns);
**exposure period from most recent miglustat treatment start date up to and including NPC Registry enrolment day; †period from Registry start to last follow-up
visit; ‡period from most recent miglustat treatment start date prior to enrolment up to last follow-up visit in the NPC Registry. EI, early-infantile onset; LI, late-
infantile onset; JUV; juvenile onset; AA, adolescent/adult onset
Fig. 2 Proportions of patients who received continuous miglustat therapy during follow up* and were categorized as ‘improved/stable’. *The length of
the observation period varied for each patient; data values based on all patients with available data, per age at neurological onset subgroup. EI, early-
infantile onset; LI, late-infantile onset; JUV; juvenile onset; AA, adolescent/adult onset. Note: six patients had insufficient disability scale data
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Fig. 3 Annual progression rate in patients who received continuous miglustat therapy between enrolment and last follow up. Data are means ±
95 % CI; no 95 % CI could be calculated for the early infantile-onset group due to the low number of patients. EI, early-infantile onset; LI, late-
infantile onset; JUV; juvenile onset; AA, adolescent/adult onset. Note: six patients had insufficient disability scale data.
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veloped a new occurrence of neuropathy during follow-
up. ‘Other’ adverse events included one case each of:
loss of consciousness and circulatory collapse; chronic
diarrhea; new seizures; and dental cavities. In the
patient who had dental cavities, miglustat was adminis-
tered in a sugary beverage. The diarrhea and theTable 3 Safety information before miglustat initiation and during N
Safety information/event Time period
Seizures Pre-treatment: present
During follow-up: worsened*
During follow-up: new*
Thrombocytopenia Pre-treatment: present
During follow-up: present*
Tremor Pre-treatment: present
During follow-up: worsened*
During follow-up: new*
Neuropathy Pre-treatment: present
During follow-up: worsened*
During follow-up: new*
Chronic diarrhea‡ Pre-treatment: present
During follow-up: present*
Other†† During follow-up: present*
*Event occurred at least once during follow-up; **percentages calculated according to nu
and 10 moderate thrombocytopenia (51–100 × 109/L); ‡diarrhea lasting >3 months; ††oth
collapse, chronic diarrhea and new seizures (all n = 1)seizures were double-reported, once under the actual
term and once under ‘other AE’.
Discussion
Here, we present a longitudinal analysis of functional dis-
ability in 92 miglustat-treated patients included from the
international NPC Registry. The 92 patients describedPC Registry follow up
Patients, N Patients with events, n (%)**
90 21 (23)
39 13 (33)
39 13 (33)
90 18 (20)
80 43† (54)
91 23 (25)
91 6 (7)
91 2 (2)
90 4 (4)
91 7 (8)
91 1 (1)
91 2 (2)
92 10 (11)
92 4 (4)
mber of patients with available data; †38 mild thrombocytopenia (101–150 × 109/L)
er adverse events comprised: dental cavities, loss of consciousness and circulatory
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observation period of 2 years in the Registry. It should be
noted that while the NPC Registry is a disease registry, we
only describe findings from miglustat-treated patients here.
Functional disability, evaluated using an established
disease-specific scale based on ambulation, manipula-
tion, language, and swallowing [3, 8], remained stable in
most NP-C patients during continuous miglustat ther-
apy, and improved in some of them. This is in line with
published data from previous studies with miglustat. A
retrospective cohort study in 66 NP-C patients demon-
strated stable or improved neurological manifestations
(using the same composite disability scale employed in
the NPC Registry) in over three-quarters of patients dur-
ing miglustat therapy over a median (range) of 1.46
(0.05–4.51) years [3, 8]. Ambulation and swallowing
were also shown to be stable or improved in miglustat-
treated adults of a randomized, controlled clinical trial
[5]. A pediatric sub-study conducted in parallel with the
main randomized trial showed similar findings in children
aged 4–12 years [5].
The low number of treatment-naïve patients currently
enrolled in the NP-C Registry, and the differences in disease
characteristics between these patients and enrolled, treated
patients, prevented comparative analyses of miglustat treat-
ment effectiveness. Nevertheless, a degree of comparison
can be drawn against natural history data from two pub-
lished retrospective cohort studies, which assessed disease
progression from diagnosis to the start of miglustat therapy.
Similar to the Registry, patients in these retrospective co-
horts were assessed based on observational methods, from
comparable regions and ages at diagnosis [8, 15]. The mean
(95 % CI) annual progression rates reported in these two
analyses were 0.11 (0.04, 0.18) score units/year in 66 pa-
tients over a mean (SD) of 3.1 (3.4) years [8], and 0.12
(0.09, 0.15) score units/year in 57 NP-C patients over a
mean (SD) of 5.5 (4.8) years [15]. In the current NPC Regis-
try cohort of miglustat-treated patients, mean (95 % CI) dis-
ease progression appears slower (0.038 [0.018, 0.059] score
units/year) than that observed among untreated patients in
the retrospective cohort studies.
When comparing the annual disease progression of the
treated patients from the Registry with the annual disease
progression of treated patients in the retrospective cohort
[8], it appears that the mean (95 % CI) progression rate in
the Registry cohort was greater (0.038 [0.018, 0.059]), than
that reported during miglustat treatment in the retrospect-
ive cohort (−0.01 [−0.08, 0.06]) [8]. However, the progres-
sion rate reported for the retrospective cohort was based
on the first 1.5 years of miglustat treatment (i.e., from treat-
ment start), whereas the progression rate calculated for the
Registry cohort was based on patients who had already re-
ceived an average of 1.9 years of miglustat therapy before
the observation period. Hence, despite being further alongin their treatment course, a large proportion of the Registry
patients still showed no progression of neurological disease.
Our analysis of annual disease progression revealed a
trend for slower progression in the later neurological on-
set subgroups and more rapid progression in earlier
neurological onset subgroups, which is in line with pre-
vious data [1, 8, 15, 16]. Even though disease progression
was fastest among the infantile-onset subgroups in this
study, stable/improved neurological disease was ob-
served in 33 % (early infantile) to 50 % (late infantile) of
treated patients.
Given the progressive, degenerative nature of NP-C, it
is difficult to distinguish safety-related, treatment emer-
gent adverse events from those related to disease pro-
gression. Nevertheless, based on the safety information
reported here we consider that no unexpected safety
findings were recorded during the NPC Registry obser-
vation period. The most common safety-relevant find-
ings were chronic diarrhea (11 %), thrombocytopenia
(54 %) and seizures (33 %). Gastrointestinal disturbances
such as mild or moderate diarrhea and flatulence have
previously been reported as transient in clinical practice
and during clinical trials with miglustat [4, 17, 18].
The high rate of thrombocytopenia among patients in
this NPC Registry cohort may be explained by the high
proportion of patients in the Registry who had ongoing
splenomegaly (39 %): patients with ongoing splenomeg-
aly are more likely to exhibit a mild or moderate degree
of thrombocytopenia [3].
Seizures were present in 23 % of NPC Registry patients
before miglustat therapy, and during the observation
period, new seizures were reported in 33 % of treated pa-
tients. It is well known from the literature that seizures
are a common feature of the natural history of NPC, and
NPC Registry data on seizures that occurred before miglu-
stat therapy (‘pre-miglustat’) support this. Effective seizure
control using anti-epileptic agents is considered crucial in
optimizing patient quality of life [2, 19].
New occurrences of tremor and neuropathy were rela-
tively infrequent during the observation period. Again,
however, it should be borne in mind that 25 % of NPC
Registry patients had tremor and 4 % had neuropathy
before miglustat initiation.
The clinical profile of miglustat-treated patients from
the Registry presented in this paper is consistent with data
from previous large cohort studies [1, 11, 12, 20, 21]. The
disease characteristics at enrolment of this miglustat-
treated group were similar to those reported for the whole
NPC Registry cohort as of March 2012, where data from
both miglustat-treated and untreated patients were pooled
[14]. In addition, the estimated overall participation rate for
European countries at the time of data analysis was high
(63 %). Given this high rate of patient/physician participa-
tion, as well as the wide global coverage of participating
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registry patients can be considered representative of the
overall NP-C patient population treated with miglustat,
both within the Registry and globally.
This analysis comes with some limitations in terms of
recruitment and data interpretation. The fact that the
majority of patients with a confirmed diagnosis of NP-C
are currently being treated with miglustat has the draw-
back that there are only a few treatment-naïve patients
available for comparison. Moreover, as per health
authority commitments, patient recruitment in the NPC
Registry is primarily focused on countries where miglu-
stat is approved for the treatment of NP-C. Physicians
may not treat patients if they consider miglustat therapy
unsuitable for them. For instance, miglustat therapy is
not recommended for patients without neurological
manifestations [2, 4]. Some patients, in particular
pediatric patients, might not be treated with miglustat
due to difficulties swallowing a capsule, and some pa-
tients might be considered as too severely affected by
the disease to benefit from treatment. The Registry un-
treated cohort therefore might not represent the full
spectrum of the disease, and as a consequence untreated
Registry patients are considered to be inadequate con-
trols for the treated group. This precludes meaningful
comparative analyses of the effectiveness of miglustat
therapy.
Another limitation is the retrospective nature of data
collection regarding onset of neurological manifesta-
tions, which might be subject to recall bias, especially in
older patients for whom onset of neurological manifesta-
tions may be in the distant past. Despite this potential
threat of patient misclassification, the most common dis-
ease forms are late-infantile and juvenile- onset NP-C,
as previously described [22].Conclusion
In summary, this miglustat-treated NP-C cohort is
considered representative of the diagnosed and treated
NP-C population, displaying typical neurological mani-
festations across the age-at-neurological onset groups.
The majority of patients showed stable or improved
neurological manifestations during an average of 2 years
of miglustat therapy.
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